Less Ads, More Data, More Tools Register for FREE

Pin to quick picksElementis Regulatory News (ELM)

Share Price Information for Elementis (ELM)

Share Price is delayed by 15 minutes
Get Live Data
157.00    2.40 (1.55%)
Bid:
156.80
Ask:
157.00
Spread: 0.20 (0.128%)
Market Cap: £895.35m
ELM Live PriceLast checked at - London Stock Exchange

Intraday Elementis Share Chart

AGM Trading Statement

26 Apr 2022 07:00

RNS Number : 2756J
Elementis PLC
26 April 2022
 

Elementis plc

AGM Trading Statement

 

Robust first quarter trading performance

 

Chromium strategic review

 

Elementis plc ("Elementis" or the "Group"), a global specialty chemicals company, today issues a trading update for the three months ended 31 March 2022 and announces a strategic review of Chromium.

First Quarter Business Performance

 

Trading for the three months ended 31 March 2022 has been positive. Revenue increased approximately 7% on an underlying basis* against the prior year period, driven by pricing actions, new business wins and continued demand recovery in Personal Care.

· Coatings revenue and margins increased on the prior year period. Successful pricing actions and an improved mix more than offset lower volumes linked to supply chain disruptions and weaker industrial activity in China, as well as rising raw material, energy and logistics cost inflation.

 

· Personal Care performance improved materially as social restrictions eased further and our growth initiatives continued to gain momentum. Margins were strong due to successful pricing actions. The ramp-up of our new plant in India continues to progress at pace.

 

· In Talc, while successful pricing actions more than offset cost inflation, performance declined on the prior year period due to weaker European automotive production and a strike throughout the first quarter at our main paper customer in Finland.

 

· Chromium performance declined as an unexpected temporary plant outage impacted volumes. Pricing continued to show positive momentum, more than offsetting increased costs.

 

Cash generation in the first quarter was in line with expectations and the Group's business model remains highly cash generative.

 

Strategic Update

 

The Group today announces it has initiated a strategic review of its Chromium business. The review will establish whether the full potential of Chromium can best be delivered as part of Elementis, or, via a full or partial divestment. It will consider the practicality of all options, whilst prioritising the best interests of all stakeholders, including employees, customers and shareholders.

 

Outlook

 

The year has started well with improved profitability, driven by self-help actions, positive momentum in Personal Care and underlying strength in Coatings. For the full year, we are confident that further strategic progress will drive improved financial performance and a reduction in leverage, in line with expectations.

 

Commenting on today's announcement, CEO, Paul Waterman said,

 

"We have made a good start to the year and will continue to maintain our focus on self-help actions and effectively managing the challenging external supply chain environment, demand uncertainties and rising inflation. We remain on-track to deliver $50m of new business opportunities, over 20 new products and progress towards $10m of additional efficiency savings by 2023.

 

In line with our Innovation, Growth and Efficiency strategy, we have focused Elementis on high quality Personal Care, Coatings and Talc performance additive businesses which hold enduring positions of strength in growing markets, and today represent approximately 90% of Group profits. In this context we will execute a strategic review of our Chromium business to determine whether Elementis remains the best owner."

 

Enquiries

Elementis

James Curran, Investor Relations 020 7067 2994

Tulchan

Martin Robinson 020 7353 4200

Olivia Peters

 

Notes: Adjusted for constant currency impact

 

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
TSTFLFSDSEIEFIF
Date   Source Headline
21st Sep 20223:48 pmRNSDirector/PDMR Shareholding
6th Sep 202212:52 pmRNSDirector Declaration
5th Sep 20224:14 pmRNSAdditional Listing
1st Sep 202212:39 pmRNSHolding(s) in Company
1st Sep 20229:15 amRNSBlock listing Interim Review
1st Sep 20229:00 amRNSTotal Voting Rights
2nd Aug 20227:00 amRNSHalf-year Report
1st Aug 202211:08 amRNSTotal Voting Rights
21st Jul 20223:14 pmRNSHolding(s) in Company
1st Jul 20229:47 amRNSTotal Voting Rights
20th Jun 20221:54 pmRNSHolding(s) in Company
17th Jun 20224:35 pmRNSPrice Monitoring Extension
3rd May 202210:27 amRNSTotal Voting Rights
3rd May 20227:00 amRNSCompany Secretary Change
26th Apr 202212:28 pmRNSResult of AGM
26th Apr 20227:00 amRNSAGM Trading Statement
5th Apr 20224:17 pmRNSDirector/PDMR Shareholding
23rd Mar 20223:52 pmRNSAdditional Listing
22nd Mar 20224:18 pmRNSAnnual Financial Report & Notice of AGM
15th Mar 20227:53 amRNSDirectorate Change
8th Mar 202212:18 pmRNSDirector/PDMR Shareholding
8th Mar 202212:17 pmRNSDirector/PDMR Shareholding
8th Mar 202211:47 amRNSHolding(s) in Company
8th Mar 202210:43 amRNSDirector/PDMR Shareholding
8th Mar 202210:39 amRNSDirector/PDMR Shareholding
7th Mar 20223:26 pmRNSHolding(s) in Company
3rd Mar 20227:00 amRNSPreliminary results year ended 31 December 2021
1st Mar 20222:03 pmRNSDirector Declaration
1st Mar 202211:18 amRNSBlock listing Interim Review
18th Jan 20227:00 amRNSTrading Update
10th Jan 20221:20 pmRNSHolding(s) in Company
4th Jan 202211:48 amRNSTotal Voting Rights
1st Dec 202111:10 amRNSTotal Voting Rights
10th Nov 202112:20 pmRNSHolding(s) in Company
3rd Nov 202111:25 amRNSHolding(s) in Company
1st Nov 20211:44 pmRNSTotal Voting Rights
28th Oct 20217:00 amRNSQ3 Trading Update
19th Oct 20216:10 pmRNSDirector Declaration
5th Oct 20218:42 amRNSDirector Declaration
1st Sep 20219:49 amRNSBlock listing Interim Review
2nd Aug 202110:22 amRNSTotal Voting Rights
29th Jul 20217:00 amRNSDirectorate Change
29th Jul 20217:00 amRNSHalf-year Report
5th Jul 202110:15 amRNSTotal Voting Rights
25th Jun 20212:59 pmRNSHolding(s) in Company
23rd Jun 20212:56 pmRNSDirector Declaration
1st Jun 202110:06 amRNSTotal Voting Rights
13th May 20213:39 pmRNSResult of AGM
13th May 20217:00 amRNSAGM Trading Statement
22nd Apr 20213:26 pmRNSAdditional Listing

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.